The US prenatal diagnostics market is one of the largest markets in the world for fetal monitoring, diagnostics, and predictive testing. It consists of a series of physician prescribed tests for monitoring maternal and fetal health. The current invasive technologies such as CVS and amniocentesis that are used to detect chromosomal abnormalities pose serious risks of miscarriages and are being replaced by the non-invasive prenatal diagnostics technologies.

Although NIPD is a relatively nascent segment of the prenatal diagnostics, it presents a lucrative growth potential to industry participants. The segment is mainly supported by rising incidences of fetal health-related abnormalities and the urgent need for safe, accurate and early diagnosis. Products such as MaterniT21 Plus, Verifi, and Harmony prenatal tests are the current tests available in the market. Around 100,000 samples were likely tested by MaterniT21 plus test alone by the first quarter of 2013 since its launch.

Further the report “US Non-Invasive Prenatal Diagnostics - Market Insight”, provides a transparent view on the present regulatory framework elaborating on the existing loopholes. A thorough analysis has been done illustrating the views of regulatory authorities, players and consumers towards the regulatory stringency, and the direction of regulations in the future have also been covered.

Currently, the US NIPD sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These companies are effectively taking steps to promote their LDTs among the US population especially targeting physicians to recommend their products. In future, the launch of Natera’s test is expected to impact the market significantly, thereby boosting the potential size and sample volume.

The report, which provides a prudent analysis on the current and future size of the market weighing the possible pessimistic and optimistic scenarios, is a must buy for new market entrants in the diagnostics field, planning to enter the prenatal segment.

Table Of Contents

1. Analyst View
2. Research Methodology
3. Statistical Snapshot - Pregnancies and Chromosomal Abnormalities
4. Overview of US Prenatal Diagnostics Market
4.1 Introduction
4.2 Prenatal Diagnostics Industry
4.2.1 Preliminary Prenatal Testing
4.2.2 First Trimester Screening
4.2.3 Second Trimester Screening
4.2.4 Chorionic Villus Sampling (CVS) Testing
4.2.5 Amniocentesis Testing
5. US Non-Invasive Prenatal Diagnostics - Market Insight
5.1 Tests Available in the Market
5.1.1 MaterniT21 (Sequenom)
5.1.2 Verifi (Verinata Health)
5.1.3 Harmony Prenatal Test (Ariosa Diagnostics)
5.1.4 Panorama (Natera)
5.2 Current and Future Market Projections to 2017
5.3 Regulatory Insight
5.3.1 Current Regulatory Scenario
5.3.2 Regulatory Authority Perspective
5.3.3 Diagnostic Test Provider Perspective
5.3.4 Consumers’ Perspective
5.3.5 Analyst Inputs
6. Current Technologies in the Market
7. Constraints in NIPD Market
8. Competitive Assessment
8.1 Ariosa Diagnostics
8.1.1 Company Overview
8.1.2 Product Overview
8.1.3 Strengths and Weaknesses
8.2 Sequenom
8.2.1 Company Overview
8.2.2 Product Overview
8.2.3 Strengths and Weaknesses
8.3 Verinata
8.3.1 Company Overview
8.3.2 Product Overview
8.3.3 Strengths and Weaknesses
8.4 Natera
8.4.1 Company Overview
8.4.2 Product Overview
8.4.3 Strengths and Weaknesses

List of Figures:

Figure 3-1: Population Base (Million), 2000-2010
Figure 4-1: Prenatal Testing Market (Billion US$), 2012-2016
Figure 4-2: Preliminary Prenatal Testing Market (Million US$), 2012-2016
Figure 4-3: First Trimester Screening Market (Million US$), 2012-2016
Figure 4-4: Second Trimester Screening Market (Million US$), 2012-2016
Figure 4-5: CVS Testing Market (Million US$), 2012-2016
Figure 4-6: Amniocentesis Testing Market (Million US$), 2012-2016
Figure 5-1: Non-Invasive Prenatal Diagnostics Market (Million US$), 2012-2017
Figure 5-2: Share of Players in Number of NIPD Tests Performed (2012)
Figure 5-3: Share of Players in NIPD Market (2012)
Figure 5-4: Forecast for Share of Players in Number of NIPD Tests Performed (2017)
Figure 5-5: Forecast for Share of Players in NIPD Market (2017)
Figure 5-6: Laboratorians’ Attitudes towards FDAs Regulations on Lab Developed Tests (LDT)

List of Tables:

Table 3-1: Number of Births and Abortions (2000-2010)
Table 3-2: Number of Multiple Pregnancies (2000-2009)
Table 3-3: Prevalence of Chromosomal Abnormalities
Table 4-1: Major Preliminary Prenatal Tests Performed
Table 4-2: Major First Trimester Screening Tests Performed
Table 4-3: Major Second Trimester Screening Tests Performed
Table 5-1: Inter-comparison of CLIA and FDA Regulatory Pathway
Table 6-1: Common Commercial Kits and Protocols for Isolation of ccff DNA from Maternal Plasma

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

  • $ 34 500
  • Industry report
  • July 2014
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 21 100
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “2014 Strategies for the Global Microbiology Testing Market” is a new seven-country strategic analysis ...

The 2014 World%s Leading Diagnostic Imaging Companies

The 2014 World%s Leading Diagnostic Imaging Companies

  • $ 14 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $14,500.  Individual company assessments $2,450.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.